W
Wim A. van der Steeg
Researcher at University of Amsterdam
Publications - 13
Citations - 1515
Wim A. van der Steeg is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Apolipoprotein B & Cholesterol. The author has an hindex of 9, co-authored 10 publications receiving 1424 citations.
Papers
More filters
Journal ArticleDOI
Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment
John J.P. Kastelein,Wim A. van der Steeg,Ingar Holme,Michael Gaffney,Nilo B. Cater,Philip J. Barter,Prakash Deedwania,Anders G. Olsson,S. Matthijs Boekholdt,David A. DeMicco,Michael Szarek,John C. LaRosa,Terje R. Pedersen,Scott M. Grundy +13 more
TL;DR: In patients receiving statin therapy, on-treatment levels of non-HDL cholesterol and apolipoprotein B were more closely associated with cardiovascular outcome than levels of LDL cholesterol.
Journal ArticleDOI
High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.
Wim A. van der Steeg,Ingar Holme,S. Matthijs Boekholdt,Mogens Lytken Larsen,Christina Lindahl,Erik S.G. Stroes,Matti J. Tikkanen,Nicholas J. Wareham,Ole Faergeman,Anders G. Olsson,Terje R. Pedersen,Kay-Tee Khaw,John J.P. Kastelein +12 more
TL;DR: When apoA-I and apoB are kept constant, HDL-C and HDL particle size may confer risk at very high values, but this does not hold true for very high levels of apo A-I at fixed levels of HDL- C and apOB.
Journal ArticleDOI
Value of Low-Density Lipoprotein Particle Number and Size as Predictors of Coronary Artery Disease in Apparently Healthy Men and Women: The EPIC-Norfolk Prospective Population Study
Karim El Harchaoui,Wim A. van der Steeg,Erik S.G. Stroes,Jan Albert Kuivenhoven,James D. Otvos,Nicholas J. Wareham,Barbara A. Hutten,John J.P. Kastelein,Kay-Tee Khaw,S. Matthijs Boekholdt +9 more
TL;DR: In this large study of individuals with moderately elevated LDL-C, LDL-P was related to CAD on top of FRS as well as after adjusting for LDL-B and the risk of future coronary artery disease (CAD).
Journal ArticleDOI
Role of the Apolipoprotein B–Apolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A Case–Control Analysis in EPIC-Norfolk
Wim A. van der Steeg,S. Matthijs Boekholdt,Evan A. Stein,K. Elharchaoui,Erik S.G. Stroes,Manjinder S. Sandhu,Nicholas J. Wareham,J. Wouter Jukema,Robert Luben,Aeilko H. Zwinderman,John J.P. Kastelein,Kay-Tee Khaw +11 more
TL;DR: The researchers found that the apo Bapo A-I ratio was a risk factor for atherosclerotic cardiovascular disease, but its ability to distinguish people who developed disease from those who did not was no better than that of the total cholesterol high density lipoprotein ratio, and it did not add further to the Framingham risk score.
Journal ArticleDOI
Inherited disorders of HDL metabolism and atherosclerosis.
G. Kees Hovingh,Eric de Groot,Wim A. van der Steeg,S. Matthijs Boekholdt,Barbara A. Hutten,Jan Albert Kuivenhoven,John J.P. Kastelein +6 more
TL;DR: Intima media thickness studies have provided evidence that hypoalphalipoproteinemia due to mutations in apoA-I, ABCA1, and LCAT is associated with increased progression of atherosclerosis, which can assist in the prioritizing of antiatherogenic therapy by increasing HDL cholesterol levels.